Trial Profile
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-095 Administered Subcutaneously to Healthy Japanese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Nov 2014
Price :
$35
*
At a glance
- Drugs ILV 095 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Pfizer; Wyeth
- 11 Nov 2014 New trial record